Dr. Christoph Antz (CEO)

Christoph is an experienced entrepreneur, company excecutive and venture capital manager in the fields of life sciences with special focus on drug, diagnostics and instrumentation development. He was a co-founder and manager of the German/US Start-Up Otogene AG and Inc., one of the first companies worldwide focussed on the development of Oto-Protective and Oto-Regenerative Drugs. Before joining Acousia, he served as CEO and Managing Director of companies like EMBL Ventures GmbH, Elara Pharmaceuticals GmbH, Abeta GmbH and Luxendo GmbH from founding up to successfull M&A. He holds a Ph.D. in physics from the University of Heidelberg and did postdocteral studies at the University Of California, San Francisco. Christoph is an alumni of the Max-Planck-Institute For Medical Research, Heidelberg.

Dr. Michael Bös (CSO)

Michael has extensive experience in Drug Discovery and Development. Before joining Acousia he served as CSO of the Munich Biotech company Affectis and successfully licensed out two programs in CNS diseases. He held several positions in Medicinal Chemistry at Roche in Basel and Nutley, NJ, USA focusing on CNS disease and Boehringer Ingelheim where he headed the MedChem department in virology research in Laval, Canada. Under his leadership 6 compounds targeting HCV and HIV were granted start of development. He received his PhD in medicinal chemistry from the University of Vienna and did his postdoctoral studies at the ETH Zurich and at Colorado State University in Fort Collins, USA